MetLife Investment Management’s Summit Therapeutics SMMT Stock Holding History

MetLife Investment Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$109K	Buy	7,508 +322	+4%	+$5.71K	﹤0.01%	2740
2026 Q1	$136K	Sell	7,186 -358	-5%	-$5.79K	﹤0.01%	2401
2025 Q4	$132K	Buy	7,544 +66	+0.9%	+$1.24K	﹤0.01%	2475
2025 Q3	$154K	Buy	7,478 +215	+3%	+$5.21K	﹤0.01%	2455
2025 Q2	$155K	Sell	7,263 -47,428	-87%	-$1.08M	﹤0.01%	2316
2025 Q1	$1.05M	Sell	54,691 -715	-1%	-$14.3K	0.01%	1338
2024 Q4	$989K	Buy	55,406 +3,981	+8%	+$77.2K	0.01%	1420
2024 Q3	$1.13M	Hold	51,425	–	–	0.01%	1331
2024 Q2	$401K	Sell	51,425 -11,893	-19%	-$64.2K	﹤0.01%	1846
2024 Q1	$262K	Hold	63,318	–	–	﹤0.01%	2044
2023 Q4	$165K	Hold	63,318	–	–	﹤0.01%	2344
2023 Q3	$118K	Hold	63,318	–	–	﹤0.01%	2494
2023 Q2	$159K	Buy	+63,318	New	+$116K	﹤0.01%	2407

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

MetLife Investment Management's SMMT Position: Q2 2026 in Review

MetLife Investment Management increased its Summit Therapeutics (SMMT) stake by 4.5% in Q2 2026, buying an estimated $5.71K and bringing the position to 7,508 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #2740.

MetLife Investment Management first reported a position in SMMT in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.13M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

MetLife Investment Management held 7,508 shares of Summit Therapeutics worth $109K as of Q2 2026.
MetLife Investment Management bought 322 Summit Therapeutics shares in Q2 2026, an estimated $5.71K.
Summit Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2740 holding.
MetLife Investment Management first reported a position in Summit Therapeutics in Q2 2023 and has held it in 13 quarters since.
MetLife Investment Management's Summit Therapeutics position peaked at $1.13M in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.